PURPOSE OF REVIEW:
The use of cannabinoids has increased since legalization of recreational and medical use in the USA. It is likely that many orthopaedic patients consume cannabinoid products during the traumatic or perioperative period. The purpose of this study was to investigate the pre-clinical data evaluating the mechanism of action of cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (Δ9-THC) and to evaluate the current clinical data on the use of cannabinoids in musculoskeletal illness.
Recent pre-clinical studies have demonstrated that cannabinoid use and the endocannabinoid system (ECS) has an important role in bone healing and bone homeostasis. There is data that suggests that the use of cannabidiol (CBD) may increase bone healing, whereas the use of Δ9-Tetrahydrocannabinol (Δ9-THC), the major psychoactive ingredient in marijuana, likely inhibits bone metabolism and repair (original abstract available at https://www.ncbi.nlm.nih.gov/pubmed/32383037).
Curr Rev Musculoskelet Med. 2020 May 8. doi: 10.1007/s12178-020-09635-x.
Cannabinoid Use in Musculoskeletal Illness: a Review of the Current Evidence.
O’Connor CM, Anoushiravani AA, Adams C, Young JR, Richardson K, Rosenbaum AJ.